Publications by authors named "Chi Man Vivienne Fong"
Article Synopsis
- Osimertinib (OSI) is a newly FDA-approved drug for non-small cell lung cancer (NSCLC) patients with the EGFR T790M mutation, but resistance to it can develop.
- Researchers created OSI-resistant NCI-H1975/OSIR cells which showed decreased proliferation but increased migration and invasion compared to normal cells, and also demonstrated resistance to multiple cancer drugs while being more sensitive to paclitaxel.
- The study revealed that loss of EGFR may contribute to OSI resistance, and navitoclax, a potential treatment, showed enhanced effectiveness against these resistant cells.
Saponins are glycosides with triterpenoid or spirostane aglycones that demonstrate various pharmacological effects against mammalian diseases. To promote the research and development of anticancer agents from saponins, this review focuses on the anticancer properties of several typical naturally derived triterpenoid saponins (ginsenosides and saikosaponins) and steroid saponins (dioscin, polyphyllin, and timosaponin) isolated from Chinese medicines. These saponins exhibit in vitro and in vivo anticancer effects, such as anti-proliferation, anti-metastasis, anti-angiogenesis, anti-multidrug resistance, and autophagy regulation actions.
View Article and Find Full Text PDF